-transparent.png){kind=logo}
N-n-propyl-norapomorphine (NPA) is 10-20 times more potent than apomorphine in producing hypomotility and inhibiting both striatal and limbic dopamine (DA) synthesis and the firing rate of nigral dopaminergic cells in rats. The threshold subcutaneous doses of NPA and apomorphine to significantly inhibit motor activity or DA synthesis are 1.25 and 24 microgram/kg, respectively. The intravenous ED 50 of NPA to inhibit dopaminergic firing is 0.36 microgram/kg and that for apomorphine is 9.1 microgram/kg. The above effects of NPA, as those of apomorphine, are antagonized by haloperidol and, stereospecifically by (--) sulpiride.
Related Publications
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
January 1982,
European journal of pharmacology,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
July 1982,
European journal of pharmacology,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
August 2000,
Nuclear medicine and biology,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
December 1979,
Archives internationales de pharmacodynamie et de therapie,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
December 1978,
Archives of neurology,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
February 2004,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
February 1985,
The Journal of pharmacology and experimental therapeutics,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
October 1983,
Journal of medicinal chemistry,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
June 1980,
Nature,
A Argiolas, and
G Mereu, and
G Serra, and
M R Melis, and
F Fadda, and
G L Gessa
April 1985,
Naunyn-Schmiedeberg's archives of pharmacology,
